AU2012322453B2 - Compositions comprising salbutamol sulphate - Google Patents

Compositions comprising salbutamol sulphate Download PDF

Info

Publication number
AU2012322453B2
AU2012322453B2 AU2012322453A AU2012322453A AU2012322453B2 AU 2012322453 B2 AU2012322453 B2 AU 2012322453B2 AU 2012322453 A AU2012322453 A AU 2012322453A AU 2012322453 A AU2012322453 A AU 2012322453A AU 2012322453 B2 AU2012322453 B2 AU 2012322453B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
propellant
drug
mdi
container
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012322453A
Other languages
English (en)
Other versions
AU2012322453A1 (en
Inventor
Stuart Corr
Timothy James Noakes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orbia Advance Corp SAB de CV
Original Assignee
Mexichem Amanco Holding SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mexichem Amanco Holding SA de CV filed Critical Mexichem Amanco Holding SA de CV
Publication of AU2012322453A1 publication Critical patent/AU2012322453A1/en
Application granted granted Critical
Publication of AU2012322453B2 publication Critical patent/AU2012322453B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/124Aerosols; Foams characterised by the propellant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/002Details of inhalators; Constructional features thereof with air flow regulating means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/009Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012322453A 2011-10-12 2012-10-12 Compositions comprising salbutamol sulphate Active AU2012322453B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201117621A GB201117621D0 (en) 2011-10-12 2011-10-12 Compositions
GB1117621.1 2011-10-12
PCT/GB2012/052542 WO2013054135A1 (en) 2011-10-12 2012-10-12 Compositions comprising salbutamol sulphate

Publications (2)

Publication Number Publication Date
AU2012322453A1 AU2012322453A1 (en) 2014-04-17
AU2012322453B2 true AU2012322453B2 (en) 2015-06-18

Family

ID=45091933

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012322453A Active AU2012322453B2 (en) 2011-10-12 2012-10-12 Compositions comprising salbutamol sulphate

Country Status (12)

Country Link
US (1) US9114164B2 (cg-RX-API-DMAC7.html)
EP (1) EP2766005B1 (cg-RX-API-DMAC7.html)
JP (1) JP5818290B2 (cg-RX-API-DMAC7.html)
CN (1) CN103857388B (cg-RX-API-DMAC7.html)
AU (1) AU2012322453B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014008609B1 (cg-RX-API-DMAC7.html)
CA (1) CA2851764C (cg-RX-API-DMAC7.html)
ES (1) ES2556585T3 (cg-RX-API-DMAC7.html)
GB (1) GB201117621D0 (cg-RX-API-DMAC7.html)
MX (1) MX336225B (cg-RX-API-DMAC7.html)
WO (1) WO2013054135A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201402234B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
WO2016102952A1 (en) 2014-12-22 2016-06-30 Aluztra Bio Ltd Prevention and treatment of metastatic disease in thrombocytotic cancer patients
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
BR122020022602B1 (pt) * 2015-12-04 2024-03-05 Mexichem Fluor S.A. De C.V. Composição farmacêutica
AU2017328910B2 (en) 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
ES2892673T3 (es) * 2016-09-19 2022-02-04 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
WO2018051132A1 (en) * 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
US11260052B2 (en) * 2016-09-19 2022-03-01 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition
FR3130554B1 (fr) 2021-12-20 2024-10-18 Aptar France Sas Composition pharmaceutique comprenant du salbutamol
FR3137830A1 (fr) 2022-07-13 2024-01-19 Aptar France Sas Composition pharmaceutique comprenant du salbutamol
US12383516B1 (en) 2025-01-06 2025-08-12 Amphastar Pharmaceuticals, Inc. Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105152B1 (en) * 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
EP0617610B1 (en) 1991-12-18 1997-03-19 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
HUT77775A (hu) 1994-12-22 1998-08-28 Astra Aktiebolag Aeroszolformák
HU219899B (hu) 1995-04-14 2001-09-28 Glaxo Wellcome Inc. Inhalálóberendezés flutikaszon-propionát adagolására mért dózisban
PL195212B1 (pl) * 1997-09-29 2007-08-31 Nektar Therapeutics Preparat bioaktywny w postaci proszku i sposób jego wytwarzania
US6103266A (en) 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
CN1150890C (zh) 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
GB2392164B (en) 1999-09-11 2004-04-07 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
CN1144582C (zh) 2000-11-28 2004-04-07 中国药科大学 治疗呼吸系统疾病的无氟里昂药用气雾剂
CN1216600C (zh) 2002-04-24 2005-08-31 信谊药厂 盐酸左旋沙丁胺醇气雾剂及制备工艺
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
WO2006004646A1 (en) 2004-06-28 2006-01-12 Nektar Therapeutics Aerosol formulation comprising nicotine salt
WO2007020204A2 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
GB0915106D0 (en) 2009-08-28 2009-10-07 Glaxo Group Ltd Process

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105152B1 (en) * 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations

Also Published As

Publication number Publication date
BR112014008609B1 (pt) 2022-04-12
JP2014530231A (ja) 2014-11-17
ZA201402234B (en) 2015-03-25
CN103857388A (zh) 2014-06-11
US20140286877A1 (en) 2014-09-25
JP5818290B2 (ja) 2015-11-18
MX2014004364A (es) 2014-05-27
GB201117621D0 (en) 2011-11-23
US9114164B2 (en) 2015-08-25
WO2013054135A1 (en) 2013-04-18
ES2556585T3 (es) 2016-01-19
CN103857388B (zh) 2016-09-28
BR112014008609A2 (pt) 2017-04-18
EP2766005A1 (en) 2014-08-20
CA2851764C (en) 2017-02-14
CA2851764A1 (en) 2013-04-18
EP2766005B1 (en) 2015-11-25
AU2012322453A1 (en) 2014-04-17
MX336225B (es) 2016-01-12

Similar Documents

Publication Publication Date Title
AU2012322453B2 (en) Compositions comprising salbutamol sulphate
AU2012322455B2 (en) Compositions comprising salbutamol sulphate
CA3007050C (en) Pharmaceutical composition comprising a formoterol compound
AU2019201520C1 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)